2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult, Animal Model
PAPER

3176 Is the combination of CSA plus TPO-ras with calcineurin inhibitors a viable and safe alternative to ATG plus CSA regimens in suitable patients with severe aplastic anemia

Ana Plesca, MD, Serhan Unlu, MD2, Karol K Gostomczyk3, Zachary Brady, BS4, Mark David Orland, MD, PhD5, Akram Abushamma, MD6, Atsushi Marumo, MD7, Arda Durmaz, PhD8, Charlotte Zurowski9, Jackson Hensley, N/A10, Luca Guarnera, MD11, Aashray Mandala12, Nandini Rajaram Siva, MD13, Varun K. Venkatesh, N/A14, Ajitesh Reddy Busireddy, N/A15, Maxwell Hou, N/A16, Kartik Lakhotiya, MS17, Carmelo Gurnari, MD,PhD18, Carlos Bravo-Perez, MD19, Chantana Polprasert, MD20, Valeria Visconte, PhD21, Abhay Singh, MD, MPH22, Akriti G Jain, MD, FACP23, Hetty Carraway, MD, MBA24, Jaroslaw P. Maciejewski, MD, PhD, FACP25
1 Cleveland Clinic Foundation, Cleveland, Ohio, United States
2 Cleveland Clinic Foundation, Cleveland, Ohio, United States
3 Cleveland Clinic Foundation, Cleveland, Ohio, United States
4 Cleveland Clinic Foundation, Cleveland, Ohio, United States
5 Cleveland Clinic Foundation, Cleveland, Ohio, United States
6 Cleveland Clinic Foundation, Cleveland, Ohio, United States
7 Cleveland Clinic Foundation, Cleveland, Ohio, United States
8 Cleveland Clinic Foundation, Cleveland, Ohio, United States
9 Cleveland Clinic Foundation, Cleveland, Ohio, United States
10 Cleveland Clinic Foundation, Cleveland, Ohio, United States
11 Cleveland Clinic Foundation, Cleveland, Ohio, United States, University of Rome Tor Vergata, Rome, Italy
12 Cleveland Clinic Foundation, Cleveland, Ohio, United States
13 Cleveland Clinic Foundation, Cleveland, Ohio, United States
14 Cleveland Clinic Foundation, Cleveland, Ohio, United States
15 Cleveland Clinic Foundation, Cleveland, Ohio, United States
16 Cleveland Clinic Foundation, Cleveland, Ohio, United States
17 Cleveland Clinic Foundation, Cleveland, Ohio, United States
18 Cleveland Clinic Foundation, Cleveland, Ohio, United States
19 Cleveland Clinic Foundation, Cleveland, Ohio, United States, Hospital Universitario Morales Meseguer, University of Murcia, IMIB-Pascual Parrilla, CIBERER - Instituto de Salud Carlos III, Murcia, Spain
20 Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand, Cleveland Clinic Foundation, Cleveland, Ohio, United States
21 Cleveland Clinic Foundation, Cleveland, Ohio, United States
22 Cleveland Clinic Foundation, Cleveland, Ohio, United States
23 Cleveland Clinic Foundation, Cleveland, Ohio, United States
24 Cleveland Clinic Foundation, Cleveland, Ohio, United States
25 Cleveland Clinic Foundation, Cleveland, Ohio, United States, Cleveland Clinic Foundation, Cleveland, Ohio, United States

Introduction
Immunosuppressive therapy (IST) with antithymocyte globulin (ATG), cyclosporine (CSA), and thrombopoietin receptor agonists (TPO-RAs) has been a standard first-line treatment for severe aplastic anemia (sAA). Recent trials have shown that adding TPO-RAs to IST improves response rates in patients with sAA without increasing toxicity or early clonal evolution. [1] Many patients who are not eligible for IST therapy with ATG have limited treatment options. Addition of eltrombopag to CSA regimen in index cases who were unfit or refused hospitalization for administration of ATG resulted in excellent responses, raising the question whether CSA plus eltrombopag combination may be a competitive alternative to ATG-based regimens, in particular when definitive treatment with ATG can be prudently delayed. Prior reports suggest efficacy of CSA plus TPO-RAs, but real-world data remains limited.[2] 

Aim
We evaluated the efficacy and safety of CSA plus eltrombopag compared to standard ATG-based regimens in patients with newly diagnosed sAA, including those ineligible for ATG. 

Results
In this retrospective, single-center study, we compared the efficacy and safety of ATG plus CSA with or without TPO-RAs vs. CSA plus TPO-RAs as first-line therapy in patients with sAA. The primary endpoint was overall hematologic response at 6 months. Secondary endpoints include complete response at 3- and 12-month points, and durability of response. Rate of adverse events and predictors of outcome, including genomic profiling and presence of PNH clone or hemolytic PNH, were included in a covariate analysis. Patients receiving CSA plus eltrombopag were ineligible for ATG due to age, comorbidities, prior hypersensitivity, transplant strategy, or treatment preference. Complete response criteria was defined as achieving Hb >10 g/dL, Platelets >100,000/µL, ANC >1,000/µL, and partial response was represented by Hb increase >1 g/dL (Hb >7 g/dL) with reduced transfusions; platelets >20,000/µL with reduced transfusions; and ANC>500/µL.

We included 115 patients; 34 received triple therapy (group A), 52 received ATG plus CSA (group B), and 29 received calcineurin inhibitors and CSA plus eltrombopag (group C). Patients treated with non-ATG-based regimens were older (median age 64 years (C) vs. 53 years (B) and 46 years (A), respectively, p=0.005), with equal gender distribution. Similarly, baseline hematologic parameters of severity did not significantly differ between groups.

Overall response (OR) rates at 6 months were 82%, 72%, and 67% in groups A, B, and C, respectively (p=0.39). Complete response rate (CRR) at 6 months was 54%, 41%, and 25% for groups A, B, and C, respectively. At 12 months, ORR was 96.3%, 87.1%, and 80% in groups A, B, and C, respectively (p=0.243). CRR at 12 months was 77.7%, 74%, and 40% for groups A, B, and C (p=0.484). In all three groups, some patients achieved early response; 1-month ORR was 44.8%, 48.8%, and 44.8% (p=0.923) for groups A, B, and C, respectively. ATG-containing regimens were associated primarily with infusion-related reactions: rash, rigors, and fever, whereas fatigue and kidney dysfunction predominated with CSA plus eltrombopag.

On multivariable analysis, baseline platelet count (OR 0.85, 95% CI 0.76–0.93), baseline ANC (OR 0.11, 95% CI 0.01–0.72), and higher platelet count at 1 month (OR 1.26, 95% CI 1.10–1.55) were associated with achieving an overall response at 6 months. Treatment regimen, age, gender, mutation status, baseline hemoglobin, 1-month hemoglobin, and 1-month ANC were not significantly associated with overall response. The presence of a PNH clone was not associated with treatment response (41.0% vs. 41.6%, p=0.957).

Conclusion
ATG-based triple therapy response rate was comparable with previously reported trial results.[1] Our results suggest that CSA plus TPO-RAs may achieve overall hematologic response rates similar to those observed with ATG-containing regimens, despite being administered to an older population. These findings support exploration of CSA plus eltrombopag in a prospective randomized trial. Regimens utilizing either CSA, tacrolimus, or sirolimus may be a reasonable, effective first-line option for patients who are not candidates for ATG and require further investigation.  

New England Journal of Medicine, 2022. 386(1): p. 11–23. Blood Cancer J, 2025. 15(1): p. 119.
Ana Plesca, MD: No relevant conflicts of interest to declare.